Antibody-drug conjugates are key to Pfizer’s acquisition of Seagen

isolated antibody drug conjugates (ADCs)

Love Employee

Pfizer (NYSE: PFE) acquisition of Seagen (NASDAQ: SGEN), announced in March, is expected to complement the pharmaceutical giant’s current portfolio of oncology therapies.

Seagen focuses on antibody-drug conjugates (ADCs), a technology the company says can “harness the targeting power of antibodies

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *